GlassScriptPhysician profile
Reshma Kundapur
NPI 1164578563
$808.21
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $232 · 2023: $15.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $100.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $90.62 | 2019-2020 | |
| Pfizer INC. | $74.77 | 2019-2020 | |
| Novo Nordisk INC | $73.43 | 2019-2020 | |
| Daiichi Sankyo INC. | $70.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.47 | 2019-2020 | |
| Amgen INC. | $52.40 | 2019 | |
| Amarin Pharma, INC. | $48.37 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $48.31 | 2019-2020 | |
| Allergan, INC. | $43.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.49 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.17 | 2019 | |
| Boston Scientific Corporation | $15.98 | 2023 | Wavewriter Alpha Prime 16 |
| Corcept Therapeutics | $15.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.92 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $14.24 | 2019 | |
| Genentech USA, INC. | $13.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.13 | 2019 | |
| Endo Pharmaceuticals INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Kundapur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.